Market Research Report
Global Hairy Cell Leukemia Therapeutics Market 2019-2023
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||900616|
|Published||Content info||129 Pages
Delivery time: 1-2 business days
|Global Hairy Cell Leukemia Therapeutics Market 2019-2023|
|Published: July 30, 2019||Content info: 129 Pages||
Hairy cell leukemia is a rare, slow-growing subtype of leukemia, which accounts for about 2% of the total cases of leukemia. Technavio's hairy cell leukemia therapeutics analysis considers sales from both chemotherapies and targeted therapy. Our analysis also considers the sales of hairy cell leukemia therapeutics in North America, Europe, Asia, and the rest of the world (ROW). In 2018, the chemotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increasing prevalence of leukemia, including hairy cell leukemia, will play a significant role in the chemotherapy segment to maintain its market position. Also, our global hairy cell leukemia therapeutics market report looks at factors such as increased exposure to hazardous substances leading to hairy cell leukemia, growing geriatric population, strategic alliances. However, limited patient pool, adverse effects of chemotherapy drugs, difficulty in diagnosis may hamper the growth of the hairy cell leukemia therapeutics industry over the forecast period.
Exposure to such hazardous substances can happen due to various types of occupations such as farming, working in manufacturing plants dealing with hazardous chemicals and fumes, and working in coal mines, cement- and gravel-producing plants. Exposure to chemical fertilizers and pesticides is continuously increasing as the lack of nutrients in the soil has increased the use of fertilizers to provide required nutrients and to improve agriculture yields. Thus, to meet the food demand of the ever-increasing population, chemical fertilizers are increasingly used, which is expected to increase the prevalence of hairy cell leukemia which, in turn, will lead the expansion of the global hairy cell leukemia therapeutics market at a CAGR of over 6% during the forecast period.
The global hairy cell leukemia therapeutics market has been witnessing some advances in research since the beginning of the 21st century, which have led to the launch of a few novel therapies for the treatment of hairy cell leukemia and other hematologic malignancies. The strong prevalence of various types of blood cancer at the global level has necessitated the need for the development of advanced therapies, such as kinase inhibitors and gene therapies, to treat such conditions. Such advents of novel therapies are likely to offset the challenges posed by the adverse effects of chemotherapy drugs in the future: which will contribute to the growth of the market during the forecast period.
For the detailed list of factors that will drive the global hairy cell leukemia therapeutics market during the forecast period 2019-2023, view our report.
With the presence of several major players, the global hairy cell leukemia therapeutics market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hairy cell leukemia therapeutics manufacturers, that include AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, and Pfizer Inc.
Also, the hairy cell leukemia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.